Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › teriflunomide

teriflunomide

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of teriflunomide

15 trials tracked of teriflunomide: 11 in phase 3 or 4 and 7 with published results. The most-cited published study has 217 citations.

15Trials tracked
11Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 2 Phase 3 9 Phase 2 4
  1. Phase 3 Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis Completed · 217 cited
  2. Phase 3 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Completed · 194 cited
  3. Phase 3 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Completed · 194 cited
  4. Phase 3 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Completed · 81 cited
  5. Phase 3 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) Completed · 48 cited
  6. Phase 4 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed · 43 cited
Show 9 more trials
  1. Phase 4 MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV Completed · 7 cited
  2. Phase 3 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed
  3. Phase 3 A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Completed
  4. Phase 3 An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis Completed
  5. Phase 3 Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis Completed
  6. Phase 2 Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis Completed
  7. Phase 2 Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis Completed
  8. Phase 2 Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis Completed
  9. Phase 2 Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
Neurology FDA Approval
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults The FDA approved a new monthly self-injection drug for multiple sclerosis
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults.
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
FDA Apr 3, 2026
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Neurology RCT
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…
Mar 27, 2026